Introduction
============

Esophageal cancer (EC) remains the sixth most common cause of cancer related death in the world despite recent progress in multimodal therapy concepts involving neoadjuvant therapy and standardized surgical approaches ([@b1-ol-0-0-10020]). EC is associated with high malignant potential for local invasion and early dissemination resulting in low overall-survival (OS) rates in patients even after curatively intended surgery ([@b2-ol-0-0-10020]).

There are two major histological types of EC that account for \>90% of all malignant neoplasms in the esophagus: squamous cell carcinoma and adenocarcinoma. The pathogenesis in adenocarcinoma is generally considered to be driven by epithelial metaplasia, often caused by acid reflux. In squamous cell carcinoma, malignant transformation is predominantly associated with alcohol intake and smoking ([@b3-ol-0-0-10020]). The incidence of the particular subtypes has changed in the past years with increase of adenocarcinoma and decrease of squamous cell carcinoma in Western countries, mainly due to life style changes ([@b2-ol-0-0-10020]). Due to the limited prognosis of the majority of patients, identification of new biomarkers predicting the individual prognosis and response to therapy are of imperative need for allocation of individualized therapy strategies.

The *TP53* gene has been known as one of the most important tumor suppressor genes, located on human chromosome 17p13.1. p53 plays a major role in tumorigenesis as it controls cell growth, apoptosis and regulation of angiogenesis ([@b4-ol-0-0-10020]). Mutations in *TP53* were found in \>50% of human cancers, which makes it one of the most mutated genes in tumors ([@b5-ol-0-0-10020]). In esophageal cancer, mutations have been described in frequencies between 40--70%, depending on the underlying cell type ([@b4-ol-0-0-10020],[@b6-ol-0-0-10020]--[@b8-ol-0-0-10020]). As shown for several tumor entities, inactivation of the *TP53* tumor suppressor gene leads to the development of malignant cell clones and accelerates the carcinogenesis ([@b9-ol-0-0-10020]). Different mechanisms of functional p53 inactivation have been described including functionally relevant point mutations and gross chromosomal alterations, mostly driven by chromosome 17p deletions.

Previous studies reported inconclusive results on whether p53 accumulation has a functional impact on progression of EC ([@b10-ol-0-0-10020]--[@b19-ol-0-0-10020]). While some studies found associations between the p53 expression level and tumor progression or overall-survival, other studies were not able to confirm these findings. Data on *TP53* deletion status is available from only one report including 40 patients suffering from esophageal squamous cell carcinoma ([@b20-ol-0-0-10020]).

To further elucidate the clinical relevance of TP53 mutations and p53 expression as prognostic biomarkers in esophageal cancer we took advantage of our preexisting tissue microarray (TMA) containing nearly 700 esophageal cancer specimens with attached clinical follow-up and clinico-pathological data.

Our findings demonstrate that strong p53 immunostaining is correlated with unfavorable prognosis in esophageal cancer, while homozygous *TP53* deletions represent a catastrophic event leading to cell death.

Materials and methods
=====================

### Patients

For this study, specimens from patients that had undergone tumor resection in curative intent between 1992 and 2014 at the University Medical Center, Hamburg-Eppendorf were included. Tissue samples from 691 patients were analyzed including 398 esophageal adenocarcinomas and 293 squamous cell carcinomas. All data including patient sex, tumor histology, size, lymph node metastasis and disease stage (UICC 7th edition) were obtained by reviewing a combination of clinical and pathological records, outpatient clinic medical records, epidemiological cancer surveillance data bases and by communication with the patients and their attending physicians. All resections were performed as en-bloc esophagectomies with radical two field lymph node dissection. Fifty patients underwent neoadjuvant therapy (AC n=30, SCC n=20). Patients that died within 30 days due to postoperative complications were not considered for survival analysis.

Informed consent was not required due to the retrospective nature this study. Analysis of anonymized human tissue samples by the treating physician (including the pathologist) is permitted according to local laws (§12a Hamburgisches Krankenhausgesetz). In addition, we obtained approval for manufacturing and analyzing tissue microarrays made from tissue samples from anonymized donors from our local review board, the Ethics Commission of the Ärztekammer Hamburg (no. WF049/09).

### TMA construction

The TMA was constructed as previously described ([@b21-ol-0-0-10020]). In brief, tissue cores were obtained from formalin-fixed paraffin-embedded (FFPE) tissue blocks from patients with pathologically proven esophageal cancer. Representative areas of the tumor were selected based on hematoxylin-eosin staining. 691 tissue cylinders with a diameter of 0.6 mm were punched from the 'donor' tissue blocks using a custom-made semi-automatic robotic precision instrument and placed into one empty recipient paraffin block. The resulting TMA blocks were used to produce 4 µm sections that were transferred to an adhesive-coated slide system (Instrumedics Inc., Hackensack, NJ, USA).

### Immunohistochemistry

Freshly cut TMA sections were immunostained on one day and in one experiment. Slides were deparaffinized and exposed to heat-induced antigen retrieval for 5 min in an autoclave at 121°C in pH 7.8 Tris-EDTA-Citrate buffer. Primary antibody specific for p53 (DO1, murine monoclonal IgG~2a~, Oncogene, Cambridge, MA; USA; dilution 1:3,600) was applied at 37°C for 60 min. Bound antibody was then visualized using the EnVision Kit (Dako, Glostrup, Denmark) according to the manufacturer\'s directions.

Colon cancers with known p53 alterations served as positive controls and normal prostate tissue as negative controls on each TMA section. Nuclear p53 staining intensity was scored in a four-step scale (0, 1+, 2+, 3+ staining intensity) and the percentage of stained nuclei was estimated. A final immunohistochemistry (IHC) result was assigned to each tumor as described in earlier studies from our group ([@b22-ol-0-0-10020]). Negative: No staining at all or 1+/2+ staining in \<10% of tumor cells, low: 1+ staining in ≥10% or 2+ staining in ≥10% but ≤70% of tumor cells or 3+ staining in ≤10% of tumor cells, high: 2+ staining in \>70% of tumor cells or 3+ staining in \>10% of tumor cells. For calculation of results low and high staining intensities were summed up as positive.

### FISH

FISH was used to identify genomic *TP53* deletions and translocations. A dual color FISH probe was constructed from a spectrum green labeled BAC clone (BACs RP11-89D11, RP11-404G1; Source Bioscience, Nottingham, UK) and a commercial spectrum orange labeled centromere 17 (CEP17) reference probe (no. 06J36-06; Abbott Molecular, Wiesbaden, Germany). Freshly cut 4 µm TMA sections were used for dual color FISH. Before hybridization, sections were deparaffinized and proteolytically pretreated with a commercial kit (paraffin pretreatment reagent kit; Abbott Molecular), followed by dehydration in 70, 80 and 96% ethanol, air drying and denaturation for 10 min at 72°C in 70% formamide-23 saline-sodium citrate (SSC) solution. Hybridization was done overnight at 37°C in a humidified chamber, slides were washed and counterstained with 0.2 mmol/l 40-6-diamidino-2-phenylindole in an antifade solution.

### FISH Scoring

Each TMA spot was carefully evaluated and the predominant *TP53* signal counts were recorded for each FISH probe. Tissue samples with missing tumor tissue as determined by corresponding H&E slides were not considered for analysis. In addition, tumor spots were excluded from analysis if there was evidence for insufficient hybridization such as lack of *TP53* signals in both tumor and peritumoral non-malignant tissue. Deletion of *TP53* was defined as presence of fewer *TP53* signals than centromere 17 probe signals (heterozygous deletion) or complete absence of *TP53* signals but presence of at least one centromere 17 probe signal (homozygous deletion) in ≥60% of tumor nuclei. The aforementioned cut-off level was chosen because a good correlation between FISH and array genomic hybridization was already shown by our group for *PTEN* and p53 in prostate cancer ([@b22-ol-0-0-10020],[@b23-ol-0-0-10020]).

### Statistical analysis

SPSS Statistics for Mac (version 17; SPSS, Inc., Chicago, IL, USA) was used for statistical analysis. Interdependence between immunostaining and FISH results as well as clinical data was calculated using the Chi-squared and Fisher\'s exact tests and displayed by cross-tables. Group differences were examined using the t-test. Survival curves were plotted using the Kaplan-Meier method and analyzed using the log-rank test. Univariate and multi-variate analyses were performed for prognostic factors of recurrence-free and overall survival using the Cox regression model. All tests were two-sided. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### p53 IHC

p53 immunostaining was interpretable in 574 (83.2%) of 691 samples, in total 314 esophageal adenocarcinomas (AC) and 260 squamous cell carcinomas (SCC) were evaluable. Reasons for non-informative cases included lack of tissue samples or absence of unequivocal cancer tissue in the TMA spot. p53 positivity was seen in 104 SCC (40.0%) and in 144 AC of the esophagus (45.9%). Representative images of p53 immunostaining in AC and SCC are given in [Fig. 1](#f1-ol-0-0-10020){ref-type="fig"}. p53 positivity was associated with tumor stage (P=0.019), UICC stage (P=0.004), grading (P=0.027) and surgical resection margin status (P=0.006) in esophageal AC ([Table I](#tI-ol-0-0-10020){ref-type="table"}), while no associations between clinico-pathological data and p53 immunostaining in squamous cell carcinoma were revealed ([Table II](#tII-ol-0-0-10020){ref-type="table"}).

### TP53 FISH analysis

FISH was interpretable for *TP53* deletions in 269 (67.6%) samples in esophageal adenocarcinoma and 237 (80.9%) samples in squamous cell carcinoma. Non-informative cases were caused by inefficient hybridization, missing tissue spots or absence of representative tumor tissue on the TMA spot. Heterozygous *TP53* deletions were detectable in 110 samples (40.9%) in EC and 46 samples (19.4%) in SCC. *TP53* deletions were associated with age (P=0.031) and surgical resection margin (P=0.029) in adenocarcinoma ([Table I](#tI-ol-0-0-10020){ref-type="table"}). For squamous cell carcinoma, associations were detected between heterozygous *TP53* deletions and tumor stage (P=0.028) and presence of lymph node metastasis (P=0.009) ([Table II](#tII-ol-0-0-10020){ref-type="table"}). Not one single TMA spot revealed cells with homozygous *TP53* deletions.

### Combined effect of p53 immunostaining and TP53 deletions

Data on both p53 immunostaining and *TP53* FISH were available from 244 adenocarcinomas and 223 squamous cell carcinomas. A correlation between high p53 immunostaining and *TP53* deletion could not be revealed for AC (P=0.643) while in SCC an association (P=0.044) was seen. In adenocarcinoma, 54 (21.8%) tumors showed heterozygous *TP53* deletion accompanied by high p53 expression which was also displayed by 25 SCC (11.2%). However, this finding was merely associated with resection margin status (P=0.013) in esophageal AC.

### Survival analysis

In total, 283 patients with adenocarcinoma and 231 with squamous cell carcinoma were available for survival analysis. High-level p53 immunostaining was linked to shortened overall-survival (OS) in both esophageal AC and SCC as analyzed by Kaplan-Meier (P=0.021 and P=0.013, respectively; [Fig. 2A and D](#f2-ol-0-0-10020){ref-type="fig"}). *TP53* deletions were not associated with OS irrespective of the histological type (P=0.973 (AC) and P=0.099 (SCC); [Fig. 2B and E](#f2-ol-0-0-10020){ref-type="fig"}). Combination of p53 expression and *TP53* deletion status did not improve the prognostic power compared to p53 IHC alone ([Fig. 2C and F](#f2-ol-0-0-10020){ref-type="fig"}).

### Multivariate analysis

For both histological types, UICC stage and a complete surgical resection (R0) proved to be independent prognostic markers as analyzed by multivariate cox-regression model. Furthermore, strong p53 immunostaining was also independently associated with OS in SCC ([Table III](#tIII-ol-0-0-10020){ref-type="table"}).

Discussion
==========

Our study shows that p53 overexpression is linked to shortened overall survival in patients suffering from EC. To our knowledge, this is the study includes the largest number of cases for EC and SCC with corresponding survival data. Furthermore, we correlated p53 IHC and TP53 FISH analysis. As follows in the discussion, previous studies either present inconclusive results or include only few patients.

In our analysis p53 alterations are present in 40--45% of esophageal cancer, irrespective of the underlying histological type. Genome studies conducted either with array comparative genome hybridization (CGH) or whole genome sequencing repeatedly revealed *TP53* mutations as the most common gene mutation in EC with reported mutation rates between 40--70% ([@b4-ol-0-0-10020],[@b7-ol-0-0-10020],[@b24-ol-0-0-10020]). The variance of the reported mutation frequencies is in concordance to immunohistochemical confirmation studies for SSC and the results revealed from our study ([@b19-ol-0-0-10020],[@b25-ol-0-0-10020]--[@b28-ol-0-0-10020]). In contrast, data from large patient cohorts concerning p53 expression in esophageal adenocarcinoma are hardly available. A recent review article by Chen and colleagues analyzed biomarkers in esophageal cancer and found only 2 studies focusing on p53 expression in esophageal adenocarcinoma with 97 patients included in the meta-analysis ([@b14-ol-0-0-10020]). These studies also showed p53 protein alterations in 40--65%, although the case load is too small to draw general conclusions. Our group has previously shown that the applied IHC protocols, for prostate cancer, reveal high concordance of IHC data with sequencing results, arguing for a strong validity of our IHC protocol ([@b22-ol-0-0-10020]).

p53 is physiologically expressed by numerous cell types and plays a major role in cell cycle control. It is considered one of the most important tumor suppressor genes ([@b9-ol-0-0-10020]). p53 mutations have been found in multiple cancers with large variances in the mutation frequency, depending on the observed tumor entity ([@b29-ol-0-0-10020]).

In our study heterozygous *TP53* deletions were found in 41% of AC and 19% of SCC. Only little data on *TP53* gene deletions have yet been reported. Recently, a study on 40 patients suffering from esophageal squamous cell carcinoma revealed heterozygous deletion of *TP53* in 22 patients (55%). A correlation with clinical data could not be established in this study ([@b20-ol-0-0-10020]). The deletion rate is somewhat higher than it is in our data, which is partially caused by our stringent criteria for defining *TP53* deletions. These were applied to avoid false deletion calling due to truncation of the nuclei during tissue sectioning. Most samples with *TP53* deletion had \>80% cells with fewer *TP53* fluorescence signals than centromere 17 signals. In contrast to other studies, we did not use automated systems for detection of particular gene deletions which is another possibility for deviating deletion rates compared to previous published reports ([@b20-ol-0-0-10020]). As already shown in prostate cancer on a TMA with \>11,000 patient samples, 100% concordance between array-CGH detected deletions and FISH could be achieved for *PTEN* and *TP53* deletions using these criteria ([@b22-ol-0-0-10020],[@b23-ol-0-0-10020],[@b30-ol-0-0-10020]). Therefore, differences in the deletion rate are explained by different protocols calling more deletions as present within one patient sample. The deletion rate of 19% supports the assumption that *TP53* deletions have only minor significance as a pathway for p53 inactivation in esophageal SCC. In line with the results revealed by our study, the impact of p53 mutations is of higher importance with respect to tumor progression than the heterozygous gene deletion of chromosome 17p13. These findings also match a Northern blot analysis on expression of the p53 gene in esophageal tumorigenesis. RNA was extracted from tumor, Barrett\'s epithelium, and histologically normal esophageal mucosa. p53 was found to be overexpressed in cancerous or metaplastic tissue in comparison to normal tissue. Thus, the authors concluded that p53 is implicated in the progression of Barrett\'s epithelium to invasive cancer ([@b31-ol-0-0-10020]).

By analyzing p53 immunostaining and *TP53* deletions, we were able to correlate p53 IHC and *TP53* deletion status with corresponding clinical data of our patient cohort. Patients with p53 overexpression in IHC presented with shortened OS and unfavorable clinic-pathological data, meaning that p53 mutations must have an influence on tumor biology. This effect is also paralleled by a significant correlation between advanced tumor stages and high p53 expression levels in AC ([Table I](#tI-ol-0-0-10020){ref-type="table"}: Tumor stage (P=0.019), UICC stage (P=0.004), grading (P=0.027) and surgical resection margin status (P=0.006)). Furthermore, the multivariate analysis of p53 immunostaining in a setting with various established prognostic factors for esophageal cancer, such as UICC stage, distant metastasis, resection margin and grading revealed that p53 accumulation is an independent prognostic marker in SCC. In contrast, in our analysis, heterozygous *TP53* deletions do not affect the OS, neither in AC nor in SCC. These results confirm the findings of former studies in EC and other tumor entities that mono-allelic protein expression is sufficient for regular cell cycle control mediated by p53 ([@b29-ol-0-0-10020]). Our data show, that mono-allelic *TP53* deletion cannot be considered a major driver for tumor progression in esophageal cancer while there is no mutation in the remaining TP53 allele.

Since the poor outcome of patients with strong p53 immunostaining was independent of the TP53 deletion status, it is tempting to speculate that these cancers may at least carry dominant negative mutations with complete inactivation of wild-type p53 protein through complex formation with mutant p53 protein. This mechanism is known to lead to massive nuclear accumulation of inactive p53 complexes composed of mutated and non-mutated p53 protein ([@b29-ol-0-0-10020]). While IHC reveals both mutated and non-mutated p53, cells with accumulation of inactive p53 complexes are the ones that will predominantly show strong staining. Thus, strong p53 immunostaining in our samples indicates an accumulation of unfunctional p53.

Alterations of p53 have been found in virtually every region of the protein but only a handful of the most frequently occurring mutations haven been studied in depth for their contribution to cancer progression ([@b32-ol-0-0-10020]). In EC, the majority of patients present with *TP53* exon single nucleotide mutations (approximately 70%) while frameshift mutations are much less frequent. Only 15% of cases have been reported to have insertions or deletions as found by genome wide sequencing and PCR exon analysis ([@b6-ol-0-0-10020],[@b32-ol-0-0-10020]). Numerous *in vitro* and *in vivo* studies confirmed the ability of mutant p53 to drive enhanced cancer invasion and motility, with evidence that mutant p53 can enhance signaling through receptors such as transforming growth factor β (TGFβ) or epidermal growth factor receptor (EGFR). Additionally, although mutated p53 has generally lost the ability to bind p53 DNA binding regions in target gene promoters, various p53 mutants can bind directly to DNA with some degree of selectivity and may thereby control the transcription of certain genes ([@b33-ol-0-0-10020],[@b34-ol-0-0-10020]). Furthermore, there is increasing evidence that mutated p53 has an inhibitory effect on transcription factors, such as TAp63, which is of regulative importance for numerous miRNA with important roles in cancer invasion and progression ([@b35-ol-0-0-10020],[@b36-ol-0-0-10020]).

In contrast to other cancers, such as prostate cancer, the combination of gene deletion and mutation status does not increase the malignant potential in esophageal cancer ([@b22-ol-0-0-10020]). In esophageal adenocarcinoma only 53 (21%) patients showed *TP53* deletion combined with strong p53 immunostaining, the rate being even lower in SCC with only 11%. These low frequencies suggest that biallelic inactivation, which is associated with a total loss of functional p53, is a catastrophic cellular event related with a high level of apoptosis. Studies using transgenic mouse models carrying heterozygous *TP53* deletions show larger and more mammalian tumors than animals with two wild type *TP53* alleles ([@b37-ol-0-0-10020]). Moreover, the results from animal studies confirm the findings in our study, as these results indicate that loss of both *TP53* alleles is not a prerequisite for tumor formation and that mere reduction in p53 levels may be sufficient to promote tumorigenesis.

Other studies have examined serum levels of p53 antibodies and their correlation to outcome. Shimada *et al* ([@b38-ol-0-0-10020]) reported on 28 patients with SCC that were positive for serum p53 antibodies out of a cohort of 105 cancers. These patients\' survival was significantly worse than that of seronegative patients. To our knowledge, no correlation between serum p53 antibody levels and p53 expression in cancer tissue has yet been described for esophageal cancer. Our study does not provide any data on this issue since serum p53 antibodies were not examined in our cohort.

Seeing that cancers with strong p53 expression are correlated with poor survival independent of the established clinic-pathological prognostic markers supports the notion that these patients might profit from neoadjuvant and adjuvant therapeutic regimes in a multimodal setting. Tumor size, nodal status and resection margin appear to not be the only relevant markers for prediction of survival in EC and therefore the search for prognostic biomarkers is warranted even in this highly malignant disease with poor overall survival even in less advanced stages.

In summary, the results of our large-scale TMA analysis in esophageal adeno- and squamous cell carcinoma show that different types of p53 alterations characterize subgroups of patients with different outcomes. Strong p53 expression is correlated with unfavorable prognosis in esophageal cancer and represents an independent prognosticator in SCC. Furthermore, homozygous *TP53* deletions are catastrophic cellular events related with a high level of apoptosis.
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###### 

Association between p53 immunostaining and *TP53* FISH with clinicopathological parameters in adenocarcinoma.

                              p53 IHC result   *TP53* FISH result                                      
  --------------------------- ---------------- -------------------- ------ ------- ----- ------ ------ -------
  All tumors                  314              54.1                 45.9           269   59.1   40.9   
  Age, years                                                               0.645                       0.031
    ≤65                       107              52.3                 47.7           91    89.2   10.8   
    \>65                      207              55.1                 44.3           178   69.9   30.1   
  Sex                                                                      0.186                       0.074
    Male                      262              52.7                 47.3           226   63.4   36.6   
    Female                    51               62.7                 37.3           42    95.9   4.5    
  Tumor stage                                                              0.019                       0.195
    pT1                       61               70.5                 29.5           40    92.2   7.8    
    pT2                       33               60.6                 39.4           26    95.9   4.1    
    pT3                       96               49.0                 51.0           156   72.8   27.2   
    pT4                       22               45.4                 54.6           21    98.1   1.9    
  Lymph node metastasis                                                    0.069                       0.923
    pN0                       96               64.6                 35.4           79    88.4   11.6   
    pN1                       51               53.0                 47.0           50    92.5   7.5    
    pN2                       81               51.9                 48.1           65    89.2   10.8   
    pN3                       84               45.2                 54.8           74    88.8   11.2   
  Distant metastasis                                                       0.475                       0.974
    M0                        277              54.9                 45.1           237   63.9   36.1   
    M1                        37               48.6                 51.4           32    95.2   4.8    
  UICC stage                                                               0.004                       0.977
    I                         62               72.6                 27.4           52    92.5   7.5    
    II                        41               61.0                 39.0           33    95.1   4.9    
    III                       173              48.0                 52.0           151   76.3   23.7   
    IV                        34               44.1                 55.9           30    95.5   4.5    
  Grading                                                                  0.027                       0.922
    G1                        15               86.7                 13.3           12    98.5   1.5    
    G2                        113              54.9                 45.1           98    84.2   15.8   
    G3                        175              50.9                 49.1           152   76.2   23.8   
    G4                        6                83.3                 16.7           3     99.6   0.4    
  Surgical resection margin                                                0.006                       0.029
    R0                        228              59.2                 40.8           174   72.7   27.3   
    R1                        78               38.5                 61.5           63    86.4   13.6   
    R2                        3                66.7                 33.3           3     99.6   0.4    

FISH, fluorescence *in situ* hybridization; IHC, immunohistochemistry; UICC, Union for International Cancer Control; het del, heterozygous deletion; no del, no deletion

###### 

Association of p53 immunostaining and *TP53* fluorescence *in situ* hybridization with clinicopathological parameters in squamous cell carcinoma.

                              p53 IHC result   *TP53* FISH result                                      
  --------------------------- ---------------- -------------------- ------ ------- ----- ------ ------ -------
  All tumors                  260              60.0                 40.0           237   80.6   19.4   
  Age, years                                                               0.678                       0.11
    \<65                      101              58.4                 41.6           94    90.3   9.7    
    \>65                      159              61.0                 39.0           143   90.3   9.7    
  Sex                                                                      0.568                       0.945
    Male                      190              61.1                 38.9           171   86.1   13.9   
    Female                    70               57.1                 42.9           66    94.5   5.5    
  Tumor stage                                                              0.694                       0.028
    pT1                       43               67.4                 32.6           42    97.9   2.1    
    pT2                       55               56.4                 43.6           46    98.3   1.7    
    pT3                       144              59.7                 40.3           134   85.2   14.8   
    pT4                       18               55.6                 44.4           15    99.2   0.8    
  Lymph node metastasis                                                    0.276                       0.009
    pN0                       123              53.7                 46.3           115   92.4   7.6    
    pN1                       58               63.8                 36.2           53    95.8   4.2    
    pN2                       52               67.3                 32.7           49    95.8   4.2    
    pN3                       26               65.4                 34.6           20    96.6   3.4    
  Distant metastasis                                                       0.873                       0.62
    M0                        211              59.7                 40.3           195   83.5   16.5   
    M1                        49               61.2                 38.8           42    97.0   3.0    
  UICC stage                                                               0.903                       0.074
    I                         60               13.1                 10.0           6     97.5   2.5    
    II                        60               14.6                 8.5            9     96.2   3.8    
    III                       91               20.8                 14.2           23    90.3   9.7    
    IV                        49               11.2                 7.3            8     96.6   3.4    
  Grading                                                                  0.63                        0.81
    G1                        3                0.4                  0.8            4     99.6   0.4    
    G2                        163              38.1                 24.6           151   88.6   11.4   
    G3                          93             21.5                 14.2           81    92.8   7.2    
  Surgical resection margin                                                0.84                        0.54
    R0                        192              43.8                 30.0           179   86.4   13.6   
    R1                          52             12.7                 7.3            45    95.3   4.7    
    R2                          14             3.1                  2.3            12    98.7   1.3    

FISH, fluorescence *in situ* hybridization; IHC, immunohistochemistry; UICC, Union for International Cancer Control; het del, heterozygous deletion; no del, no deletion

###### 

Multivariate analysis of p53 immunostaining in esophageal cancer.

                                Adenocarcinoma   Squamous cell carcinoma                                             
  ----------------------------- ---------------- ------------------------- ------- --------- ------- ------- ------- -------
  Sex (male/female)             0.741            0.462                     1.187   0.212     0.815   0.562   1.184   0.284
  Age group (\<65/\>65 years)   1.414            0.965                     2.072   0.076     0.920   0.663   1.277   0.620
  UICC Stage                    2.232            1.626                     3.065   \<0.001   1.288   1.019   1.629   0.034
  Distant metastasis            1.095            0.581                     2.063   0.780     1.001   0.579   1.730   0.998
  Surgical resection margin     1.677            1.152                     2.440   0.007     1.396   1.061   1.836   0.017
  Grading                       1.219            0.874                     1.700   0.243     1.131   0.829   1.543   0.438
  p53 immunostaining            1.186            0.829                     1.698   0.351     1.459   1.054   2.022   0.023
  *TP53* FISH                   0.853            0.593                     1.227   0.391     1.095   0.745   1.610   0.643

FISH, fluorescence *in situ* hybridization; UICC, Union for International Cancer Control; HR, hazard ratio
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